The committee supports approving the CFTR modulator for patients 2 years and older with at least one non-class I CFTR gene mutation.

Boston, USA-based biotech Sionna Therapeutics has recently raised $191 million through its initial public offering (IPO), marking a step forward in its efforts to develop treatments for cystic ...

Sionna Therapeutics recently secured an initial public offering (IPO) of $191m on the Nasdaq stock exchange, signalling ...

Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the ...

Researchers trial inhalable gene therapy for cystic fibrosis, offering a potential breakthrough in treating the genetic lung ...

A new inhalable gene therapy for cystic fibrosis (CF) has entered Phase I clinical trials, a major milestone on the journey ...

There are plenty of great investment alternatives in the healthcare sector. You won't need a boatload of money to get started ...

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis is being tested in human ...

Cystic fibrosis (CF) is caused by defects in the CFTR gene ... At present, some people with CF respond well to relatively new ...

Researchers at Imperial College London are leading human trials for the innovative treatmentAn inhalable medicine with the potential to improve lung ...

IP Group, the UK Respiratory Gene Therapy Consortium (GTC)1 and OXB,1 today announce the start of LENTICLAIRTM 1, a Phase I/II trial ...